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REGULAR ARTICLE
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Key Points
• Acalabrutinib had good
tolerability in patients
with relapsed or re-
fractory CLL who were
intolerant to ibrutinib.
• Acalabrutinib demon-
strated a high response
rate (81%) in patients
with relapsed or refrac-
tory CLL who were
intolerant to ibrutinib.
The Bruton tyrosine kinase (BTK) inhibitor ibrutinib improves patient outcomes in chronic
lymphocytic leukemia (CLL); however, some patients experience adverse events (AEs)
leading to discontinuation. Acalabrutinib is a potent, covalent BTK inhibitor with greater
selectivity than ibrutinib. We evaluated the safety and efficacy of 100 mg of acalabrutinib
twice daily or 200 mg once daily in patients with CLL who discontinued ibrutinib because
of intolerance as determined by the investigators. Among 33 treated patients (61% men;
median age, 64 years; range, 50-82 years), median duration of prior ibrutinib treatment
was 11.6 months (range, 1-62 months); median time from ibrutinib discontinuation to
acalabrutinib start was 47 days (range, 3-331 days). After a median of 19.0 months (range,
0.2-30.6 months), 23 patients remained on acalabrutinib; 10 had discontinued (progressive
disease, n 5 4; AEs, n 5 3). No acalabrutinib dose reductions occurred. During
acalabrutinib treatment, the most frequent AEs included diarrhea (58%), headache (39%),
and cough (33%). Grade 3/4 AEs occurred in 58%, most commonly neutropenia (12%)
and thrombocytopenia (9%). Of 61 ibrutinib-related AEs associated with intolerance,
72% did not recur and 13% recurred at a lower grade with acalabrutinib. Overall response
rate was 76%, including 1 complete and 19 partial responses and 5 partial responses
with lymphocytosis. Among 25 responders, median duration of response was not reached.
Median progression-free survival (PFS) was not reached; 1-year PFS was 83.4%
(95% confidence interval, 64.5%-92.7%). Acalabrutinib was well tolerated with a high
response rate in patients who were previously intolerant to ibrutinib. This trial was
registered at www.clinicaltrials.gov as #NCT02029443.
Introduction
Chronic lymphocytic leukemia (CLL), the most prevalent adult leukemia in the West,1 is a mature
B-cell malignancy characterized by proliferation and survival signals associated with chronic active
B-cell receptor (BCR) signaling2 for which Bruton tyrosine kinase (BTK) is critical.3 Understanding
the role of BTK in disease pathogenesis led to the development of ibrutinib, a covalent BTK inhibitor
that improved progression-free survival (PFS) and overall survival (OS) in patients with CLL
compared with conventional therapies.4-6 Despite the efficacy of ibrutinib, many patients with CLL
cannot maintain benefit from BTK inhibition because of the development of treatment-limiting
Submitted 14 December 2018; accepted 8 March 2019. DOI 10.1182/
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adverse events (AEs). These ibrutinib-related AEs include atrial
fibrillation, arthralgias, rash, diarrhea, and bleeding and have led
to ibrutinib discontinuation in 9% to 14% of patients in clinical
studies6-11 and;22% of patients in routine clinical practice.12-14
Ibrutinib potently inhibits BTK and leads to inhibition of BCR
signaling.15 Ibrutinib also targets many other cellular processes
through the roles of BTK outside of BCR signaling and the
inhibition of other kinases,15-18 leading to an impact upon normal
processes in T lymphocytes, macrophages, and platelets.19-28
Collectively, these effects of ibrutinib on multiple cellular processes
may influence its AE profile.
Acalabrutinib is a potent, highly selective, covalent BTK inhibitor
with minimal off-target activity.16,17,29 In vitro, acalabrutinib has
greater relative selectivity than ibrutinib for BTK over off-target
kinases such as TEC (25- vs 6.7-fold), epidermal growth factor
receptor (.200- vs 3.5-fold), and interleukin-2–inducible T-cell
kinase (.200- vs 3.3-fold).16 Acalabrutinib showed minimal activity
on nontarget cell types at physiologically relevant concentrations,
including T cells,16,30 natural killer cells,25 and epithelial cell lines.16
Additionally, thrombus formation was not impaired in platelets from
acalabrutinib-treated patients when tested in a humanized mouse
model, but it was impaired in platelets from patients receiving ibrutinib.17
On the basis of the safety and tolerability observed with
acalabrutinib in patients with relapsed or refractory CLL, including
an overall response rate (ORR; response of partial response [PR]
with lymphocytosis [PRL] or better) of 93% and estimated 18-month
PFS of 90%,17,31 we hypothesized that patients with CLL who
discontinued ibrutinib because of treatment-limiting AEs could still
derive clinical benefit from a more selective BTK inhibitor. Here, we
present the safety and efficacy of acalabrutinib treatment in patients
with relapsed or refractory CLL or small lymphocytic lymphoma (SLL)
who had previously discontinued ibrutinib because of intolerance.17,31
Patients and methods
Study design
Patients in this study were an added cohort of the open-label phase
2 dose expansion of a multicenter phase 1/2 study.17,31 The
efficacy and safety of acalabrutinib were evaluated in this cohort
of patients with CLL or SLL who were intolerant to ibrutinib, as
determined by the investigator. Patients were enrolled across
7 major US and UK academic centers. The study was conducted in
accordance with the International Conference on Harmonisation
Guidelines for Good Clinical Practice and the Declaration of
Helsinki. The institutional review board at each site approved the
protocol. All patients provided written informed consent.
The planned acalabrutinib dosage for this cohort was 100 mg twice
daily (n 5 30) and 200 mg once daily (n 5 3). Three patients
originally receiving the 200-mg once-daily dose were later switched
to 100 mg twice daily based on preclinical BTK occupancy studies;
all 3 received #56 days of initial 200-mg once-daily acalabrutinib
treatment. Acalabrutinib was continued until disease progression
or unacceptable toxicity.
Patients
Eligible patients had confirmed CLL or SLL, as defined by the Inter-
national Workshop on Chronic Lymphocytic Leukemia (IWCLL).32
Patients with ibrutinib intolerance were defined as those who were
unable to continue the medication because of ibrutinib-related
AEs, as determined by the investigator.4,5 Resolution of these AEs
was not required before initiating acalabrutinib. Patients were not
required to have disease progression before entering this study;
additionally, the initial protocol did not require measurable disease
or an indication for treatment, but it was subsequently modified. All
enrolled patients had detectable CLL. Measurable disease was
defined as $1 lymph node $2 cm, as measured in the longest
diameter. Other eligibility criteria included age $18 years and
Eastern Cooperative Oncology Group performance status #2.
Patients were excluded if they had progressed while receiving
ibrutinib. Additional exclusion criteria included absolute neutrophil
count,0.753 109/L, platelet count,503 109/L (unless there
was bone marrow involvement), known CLL central nervous
system disease involvement, and estimated creatinine clearance
,30 mL per minute. Patients with significant cardiovascular disease
(uncontrolled or symptomatic arrhythmias, congestive heart failure,
or myocardial infarction), any class 3 or 4 cardiac disease per New
York Heart Association functional classification, or corrected QT
interval .480 ms were excluded. Patients with prior or concurrent
atrial fibrillation were eligible. Concomitant treatment with warfarin
or equivalent vitamin K antagonists was prohibited; other anticoag-
ulants were permitted.
Objectives
The primary objective was to determine the safety of acalabrutinib
in patients intolerant to ibrutinib, as assessed by frequency,
severity, and attribution of AEs based on the Common Termi-
nology Criteria for Adverse Events (version 4.03). Secondary
objectives included the determination of investigator-assessed
ORR (including PRL), duration of response (DOR), and investigator-
assessed PFS. Response was evaluated using the IWCLL
criteria; however, isolated lymphocytosis was not considered to
indicate relapse.32,33 Pharmacodynamic analysis of baseline and
on-study samples and genomic analyses of baseline samples
were exploratory end points.
Study procedures
Each patient had a baseline assessment that included clinical
history, physical examination, laboratory testing, and imaging
studies. Safety assessments were based on the frequency and
severity of AEs, standard clinical laboratory tests, and mea-
surements of vital signs. Prior AEs experienced during ibrutinib
treatment were recorded at study entry. Treatment-emergent
AEs experienced during acalabrutinib treatment were classified as
recurrent AEs if the same AE had been experienced while receiving
ibrutinib. Disease status was assessed at baseline and during
the study using computed tomography, physical examination, and
laboratory tests. Radiologic tumor assessments occurred at the end
of cycles 2, 4, and 6, then every 6 cycles until cycle 36, and every
12 cycles thereafter. Bone marrow biopsy was required for confir-
mation of a complete response (CR).
Statistical analyses
Descriptive statistics (including means, standard deviations, me-
dians, and ranges for continuous variables and proportions for
discrete variables) were used to summarize data as appropriate.
Safety and efficacy were evaluated in all patients who received $1
dose of study drug. Disease parameters (imaging and laboratory
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parameters) performed at study entry were used as the baseline for
response assessment. PFS was defined as the time from the first
dose of acalabrutinib to documented disease progression or death
and estimated using Kaplan-Meier methodology; patients without
disease progression or death were censored for PFS at the time of
last follow-up.
Pharmacodynamic analysis
As described previously,17 BTK occupancy (the level of drug
binding to BTK) by acalabrutinib was measured in peripheral
blood mononuclear cells (PBMCs) with the aid of a biotin-
tagged analog probe on day 1 (predose and 4 hours postdose)
and on days 2, 8, and 28 and on day 28 of cycle 6 (predose).
The BTK occupancy was calculated relative to each patient’s
baseline control (day 1 predose). Phosphorylation of BTK on the
tyrosine 223 residue was evaluated in PBMCs stimulated with
goat anti-human immunoglobulin M F(ab9)2 (Southern Biotech)
and hydrogen peroxide using intracellular flow cytometry as
described previously.16,17
Genomic analysis
Exploratory genomic evaluation was conducted on baseline patient
samples. A targeted next-generation sequencing 220-gene panel
(Cancer Genetics Inc) was used to analyze baseline PBMC pellets.
Sequencing variants were called using VarDict from the BAM files
provided by Cancer Genetics Inc34 and then filtered to remove
sequencing artifacts (if novel and present in .40% of samples or
called in a low-sequence complexity region or a repeated region in
the genome), low-quality calls (,5 reads supporting alternative
variants, mean base quality Phred score ,25, or mean mapping
quality score ,10), and germ line single-nucleotide polymorphisms
(removed if allele frequency was .0.0025 vs population single-
nucleotide polymorphism databases [1000 Genomes Project
(phase 3) and Broad ExAC]). Additionally, variants with allele
frequency ,5% were filtered.
Data sharing statement
Data underlying the findings described in this manuscript may
be obtained in accordance with the AstraZeneca data sharing
policy.35
Results
Patients
From 11 September 2014 to 24 November 2015, 35 patients with
CLL who were considered ibrutinib intolerant were enrolled and 33
were treated with acalabrutinib; 1 was withdrawn by the investigator
(lack of active disease), and 1 withdrew consent before first dose
(pursued alternate therapy; Figure 1). Median patient age was
64 years (range, 50-82 years); 49% were age$65 years. At baseline,
many patients had high-risk disease: 27% had a Rai stage of III or IV,
31% had bulky lymph nodes, 38% had deletion of chromosome
17(p13.1) [del(17)(p13.1)], 22% had del(11)(q22.3), and 78% had
b2-microglobin .3 mg/L (Table 1).
36 Most patients (81%) had
unmutated IGHV, and 52% of patients had baseline cytopenias
Assessed for eligibility (n = 37)
Enrolled (n = 35)
Analyzed (n = 33)
Discontinued acalabrutinib (n = 10)
• Progressive disease (n = 4 [Richter transformation, n = 2])
• Adverse event (n = 3 [metastatic endometrial cancer,
      hemorrhagic stroke, Aspergillosis infection])
• Physician decision (n = 3 [concurrent hemophilia, increased
      BTK resistance, CLL CNS involvement])
Allocation
Enrollment
Follow-Up
Analysis
Allocated to treatment (n = 35)
• Received acalabrutinib (n = 33)
• Did not receive acalabrutinib (n = 2; withdrawn
      consent, investigator decision)
Excluded (n = 2)
• Did not meet inclusion criteria (n = 2)
Figure 1. Patient flow through the study. CNS,
central nervous system.
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(neutropenia in 12% [grade $3, 9%], anemia in 18% [6%], and
thrombocytopenia in 21% [12%]). Patients were heavily pre-
treated, with a median of 4 prior therapies (range, 2-13 therapies);
20 patients (61%) had received$4 lines of prior systemic therapy.
Median duration of prior ibrutinib treatment was 11.6 months
(range, 1-62 months); median duration from the end of ibrutinib to the
start of acalabrutinib treatment was 47 days (range, 3-331 days).
Thirty patients (91%) had ibrutinib as their most recent prior
treatment. Six patients with detectable CLL were treated based
on investigator and patient discretion without meeting the
conventional indication for treatment per IWCLL 2008 criteria.
The protocol was subsequently amended to require patients to
have a specific indication for treatment per IWCLL criteria. Five
of these 6 patients were dosed and evaluable for efficacy and
were transitioned immediately from ibrutinib to acalabrutinib to
avoid tumor flare that typically occurs with BTK inhibitor therapy
discontinuation.
Characterization of ibrutinib-related AEs at
study entry
Thirty-three patients reported 61 ibrutinib-related AEs that led to
intolerance at study entry; a patient could have had .1 AE
leading to ibrutinib intolerance. Patients reported a median of
1 ibrutinib-related AE (range, 1-4 AEs), most commonly rash
(24%), arthralgia (18%), diarrhea (15%), fatigue (12%), and
hemorrhage (12%; Figure 2). Ibrutinib-related AEs were grade 1, 2,
3, or 4 in 9%, 36%, 42%, and 6% of patients, respectively; 6% were
of unknown grade. The most common grade$3 AEs on ibrutinib that
led to intolerance were rash, arthralgia, and diarrhea (6% each).
Other AEs experienced during prior ibrutinib treatment and resulting
in intolerance included 2 cases of atrial fibrillation and 10 bleeding-
related AEs (hemorrhage, n5 4; hematoma, n5 2; and conjunctival
hemorrhage, contusion, ecchymosis, and subdural hematoma,
n 5 1 each).
Patient disposition
After a median of 19.0 months (range, 0.7-30.6 months) on
treatment, 23 patients (70%) remained on acalabrutinib therapy
and 10 (30%) discontinued (Figure 1). Four patients (12%)
discontinued because of progressive disease (Richter transforma-
tion, n 5 2), and 3 (9%) discontinued because of AEs (metastatic
endometrial cancer, n 5 1; hemorrhagic stroke, n 5 1 [event
occurred on study day 17 in a patient with extensive prior history of
thrombocytopenia in the setting of grade 3 thrombocytopenia]; and
Aspergillosis infection, n5 1 [patient received 2 months of ibrutinib
treatment and 2.7 months of acalabrutinib treatment]). Additionally,
3 patients (9%) discontinued because of physician decision
(concurrent hemophilia that was present at baseline, n 5 1;
increased BTK resistance, n 5 1 [patient discontinued before
meeting IWCLL criteria for disease progression]; and CLL central
nervous system involvement, n 5 1). Two deaths were reported
during the study period, 1 resulting from hemorrhagic stroke and
1 resulting from disseminated Aspergillosis infection, both noted
above.
There were no acalabrutinib dose reductions because of AEs. Nine
patients (27%) receiving acalabrutinib had dose holds (defined as
missing dose for $7 consecutive days; because of AE, n 5 1
[metastatic endometrial cancer]; delayed first dose, n 5 1; patient
error, n 5 2; procedure, n 5 3; discrepant dosing record, n 5 1;
steroid taper, n5 1; and unknown, n5 2), and 2 patients (6%) had
a temporary dose reduction (defined as taking lower dose level for
$3 consecutive days; because of patient error and surgery, n 5 1
each). Notably, only 1 of the 9 patients who had a dose hold
showed disease progression on acalabrutinib.
Safety
Events with acalabrutinib. The most common AEs of any
grade in the 33 patients irrespective of attribution were diarrhea
(58%), headache (39%), and cough (33%; Table 2); all of these
AEs were grade 1 or 2. Grade $3 AEs that occurred in .1 patient
each (.3%) included neutropenia (n5 4; 12%); thrombocytopenia
(n 5 3; 9%); and pneumonia, anemia, and hypertension (n 5 2
each; 6%). Fifteen patients (45%) experienced serious AEs, most
commonly infections (n5 10 patients, including 2 with pneumonia);
all other serious AEs occurred in 1 patient each, except for pyrexia
(n 5 2 patients).
Table 1. Baseline characteristics of all treated patients (N 5 33)
Characteristic n or n/N (%)
Age, y
Median 64
Range 50-82
Male sex 20 (61)
ECOG performance status #1 32 (97)
Rai stage III-IV 9 (27)
Bulky disease $5 cm 10/32 (31)
b2-microglobulin .3 mg/L 21/27 (78)
No. of prior therapies
Median 4
Range 2-13
Ibrutinib as most recent prior therapy* 30 (91)
Duration of prior ibrutinib treatment, mo
Median 12
Range 1-62
Time from ibrutinib end to acalabrutinib start, d
Median 47
Range 3-331
Baseline cytopenias
ANC #1.5 3 109/L 4 (12)
Hemoglobin #11.0 g/dL 9 (27)
Platelets #100 3 109/L 13 (39)
Genomic status
del(11q) 7/32 (22)
del(17p) 12/32 (38)
del(13q) 21/27 (78)
TP53 mutation 8/27 (30)
NOTCH1 mutation 2/27 (7)
SF3B1 mutation 4/27 (15)
Unmutated IGHV 25/31 (81)
ANC, absolute neutrophil count; ECOG, Eastern Cooperative Oncology Group.
*Other most recent prior therapies: venetoclax, n 5 1; methylprednisolone with rituximab,
n 5 1; investigational drug (TG02), n 5 1.
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During acalabrutinib treatment, 2 atrial fibrillation events (grade 2,
n5 1; grade 3, n5 1) and 1 atrial flutter event (grade 3, n5 1) were
reported. The grade 2 atrial fibrillation event occurred in a patient with a
medical history of paroxysmal atrial fibrillation (related to prior ibrutinib
treatment) who had discontinued an antiarrhythmicmedication 15 days
before the event. One case each of new grade 3 atrial fibrillation and
grade 3 atrial flutter occurred in the setting of an acute pulmonary
infection. No dose modification was required. Four other patients with
a medical history of atrial fibrillation or flutter did not experience
recurrence during acalabrutinib treatment. One case of de novo
supraventricular tachycardia (grade 2) occurred, requiring
hospitalization; the patient remained on study drug.
Twenty-two patients experienced bleeding events; all but 1 were
grade 1 or 2 events. Bleeding AEs that occurred in.1 patient each
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Figure 2. Change in ibrutinib-related AEs during acalabrutinib treatment. *An additional 6 events of unknown grade (rash, diarrhea, hemorrhage, decreased appetite,
dyspnea, and weight decreased) did not recur.
Table 2. AEs experienced during acalabrutinib treatment (‡15% any grade) for all treated patients (N 5 33)
AE
n (%)
Any grade Grade 1 Grade 2 Grade 3 Grade 4
Diarrhea 19 (58) 15 (45) 4 (12) 0 0
Headache 13 (39) 9 (27) 4 (12) 0 0
Cough 11 (33) 6 (18) 5 (15) 0 0
Weight increased 10 (30) 6 (18) 3 (9) 1 (3) 0
Nausea 9 (27) 6 (18) 2 (6) 1 (3) 0
Contusion 8 (24) 5 (15) 3 (9) 0 0
Upper respiratory tract infection 8 (24) 2 (6) 5 (15) 1 (3) 0
Arthralgia 7 (21) 6 (18) 1 (3) 0 0
Pyrexia 7 (21) 5 (15) 1 (3) 1 (3) 0
Vomiting 7 (21) 5 (15) 2 (6) 0 0
Fatigue 6 (18) 3 (9) 3 (9) 0 0
Myalgia 6 (18) 2 (6) 3 (9) 0 0
Rash 6 (18) 5 (15) 1 (3) 0 0
Constipation 5 (15) 4 (12) 1 (3) 0 0
Dizziness 5 (15) 3 (9) 2 (6) 0 0
Ecchymosis 5 (15) 4 (12) 1 (3) 0 0
Fall 5 (15) 3 (9) 2 (6) 0 0
Noncardiac chest pain 5 (15) 3 (9) 1 (3) 1 (3) 0
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(.3%) included contusion (n 5 8; 24%); ecchymosis (n 5 5;
15%); and epistaxis, hematuria, increased tendency to bruise,
petechiae, and rectal hemorrhage (n5 2 each; 6%). Two events
were considered major bleeding events (defined as grade $3,
serious, or affecting the central nervous system): a cerebral
microhemorrhage (grade 2) in a patient with a prior history of
stroke and hypertension and a gastric hemorrhage (grade 3) in
the setting of thrombocytopenia and immune thrombocytopenic
purpura.
Five patients (15%) experienced events of hypertension, 3 of
which were grade 3. Of these 5 patients, 3 had a medical history of
hypertension, and 2 of these 3 patients had grade 3 hypertension
AEs on study.
Ibrutinib-related AE recurrence. During treatment with
acalabrutinib, 21 patients (64%) did not experience a recurrence of
AEs that led to ibrutinib intolerance; 12 (36%) had a recurrence of
$1 event. Of the 61 ibrutinib-related AEs that led to intolerance
among the 33 patients, 44 events (72%) did not recur, and 17
ibrutinib-related AEs (28%) recurred during acalabrutinib treatment,
including 8 (13%) that recurred at a lower grade and 7 (11%) that
recurred at the same grade. Of the 9 recurrent AEs that were
grade $2 during ibrutinib treatment, 8 (89%) recurred with
decreased severity during acalabrutinib treatment (Figure 2). One
grade 2 event and 6 of the 8 grade 1 events recurred with the
same severity. Two AEs were grade 1 during ibrutinib treatment
and then recurred at grade 2 during acalabrutinib treatment
(contusion and fatigue). Fatigue, rash, myalgia, and diarrhea each
recurred in .1 patient.
As described, the most common ibrutinib-related events reported
at baseline were rash, arthralgia, diarrhea, fatigue, and hemorrhage.
Of the 8 rash events, 5 did not recur, 1 recurred at a lower grade,
and 2 recurred at the same grade (Figure 2). Of the 6 arthralgia
events, 5 did not recur and 1 recurred at a lower grade. Of the 5
diarrhea events, 3 did not recur and 2 recurred at a lower grade.
Of the 4 fatigue events, 1 did not recur, 1 recurred at a lower
grade, 1 recurred at the same grade, and 1 recurred at a higher grade.
None of the 4 hemorrhage events recurred.
Of the 10 bleeding events that occurred during ibrutinib treatment
and resulted in intolerance, 2 (contusion and ecchymosis) recurred
during acalabrutinib treatment.
Median follow-up of the 12 patients with recurrent AEs was
18.5 months (range, 0.6-26.9 months). Most ibrutinib-related
AEs recurred early with acalabrutinib treatment, with a median
time to onset of 14 days (range, 4-337 days). Of the 12 patients
with recurrent AEs, 8 continued acalabrutinib treatment and 4
discontinued because of disease progression (n 5 2 [Richter
transformation, n 5 1]) or an AE (n 5 2 [stroke and endometrial
cancer]). No patients discontinued acalabrutinib because of
recurrent ibrutinib-related AEs.
Efficacy
Investigator-assessed responses are listed in Table 3. The ORR
(PRL or better) was 76%, with 1 CR, 19 PRs, and 5 PRLs. All
patients achieved at least stable disease. Of 6 patients with
stable disease as best response, 2 had no detectable lymph-
adenopathy on imaging at baseline. Of 6 patients who did not
meet the conventional IWCLL criteria for treatment, 1 never
received acalabrutinib, 1 had a CR, 1 had a PR, and 3 had stable
disease relative to baseline disease. Notably, 2 of the 33 treated
patients did not have a response assessment; 1 patient received
5 days of acalabrutinib treatment before physician decision to
discontinue because of concurrent hemophilia, and 1 patient
received 18 days of acalabrutinib treatment before treatment
was terminated for grade 5 stroke. Median time to PRL or better
was 1.9 months (range, 1.6-19.2 months). Among the 25
responders, median DOR (PRL or better) was not reached;
82% (95% CI, 59%-93%) of the 25 responders had a DOR
$12 months. Median PFS was not reached; 1-year PFS was
83.4% (95% CI, 64.5%-92.7%); 2-year PFS was 75.0% (95% CI,
54.2%-87.4%; Figure 3).
Across risk-stratification subgroups, investigator-assessed
overall responses were similar. In patients with del(11)(q22.3),
del(17)(p13.1), and unmutated IGHV (n 5 7, 12, and 25,
respectively), ORRs (PRL or better) were 86% (95% CI,
42%-100%), 67% (95% CI, 35%-90%), and 80% (95% CI,
59%-93%), respectively. In patients with $4 prior therapies
(n 5 20), ORR was 65% (95% CI, 41%-85%) and 2-year
PFS was 76% (95% CI, 48%-91%). Median follow-up was
19.0 months (range, 12.7-28.9 months) for patients with
del(11)(q22.3), 13.6 months (range, 0.7-30.6 months) for
patients with del(17)(p13.1), 19.0 months (range, 0.7-28.9 months)
for patients with unmutated IGHV, and 17.0 months (range,
0.7-30.6 months) for patients with $4 prior therapies. Median
PFS was not reached in any of these subgroups. Three patients
Table 3. Investigator-assessed responses in treated patients (N5 33)
Best response n (%)
CR (bone marrow confirmed) 1 (3.0)
PR 19 (57.6)
PRL 5 (15.2)
Stable disease 6 (18.2)
ORR (‡ PR) 20 (60.6)
95% CI* 42.1-77.1
ORR (‡ PRL) 25 (75.8)
95% CI* 57.7-88.9
*95% exact binomial confidence interval (CI).
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had other therapies between ibrutinib and acalabrutinib: there
were no posttreatment response assessments for the patients
who received venetoclax (n 5 1) or TG02 (n 5 1); the best
response was stable disease for the patient who received
methylprednisolone with rituximab (n 5 1).
Pharmacodynamics
The pharmacodynamic response to acalabrutinib in this cohort
is shown in Figure 4. Median BTK occupancy was 98% 4 hours
postdose and remained high (.94%) over the treatment interval
at all points tested (Figure 4A). Phosphorylation of BTK at the
tyrosine 223 residue in response to ex vivo BCR stimulation was
almost fully inhibited 4 hours postdose and remained at or below
baseline at all points tested (P , .001; Figure 4B).
Genomic analysis
Where sufficient PBMCs were available from baseline non–
B cell–selected blood collections (n 5 30), genomic analysis
confirmed the absence of BTK C481S and known phospholi-
pase C-g2 (PLCg2) mutations with a .5% allelic fraction (data
not shown).31,34
Discussion
Ibrutinib provides an oral therapeutic option for both newly
diagnosed and relapsed/refractory patients with CLL. However,
treatment-emergent AEs, such as atrial fibrillation, arthralgias, rash,
diarrhea, and bleeding, lead to discontinuation in 9% to 23% of
patients,6-14 and this poor tolerability may impede clinical benefit
for patients. These treatment-emergent AEs are thought to be
mediated in part by the binding of ibrutinib to non-BTK targets.
Acalabrutinib is a more selective BTK inhibitor,16 developed to
minimize off-target kinase interactions while potently inhibiting BTK.
Results from this study demonstrate that patients with CLL who
discontinued ibrutinib treatment because of intolerance were able
to tolerate acalabrutinib treatment and achieve promising disease
control.
Patients in this study were distinctive vs patients enrolled in prior
studies with acalabrutinib or other BTK inhibitors; all were intolerant
to ibrutinib. Of the 33 patients who could not tolerate ibrutinib, only
3 discontinued acalabrutinib because of AEs. Acalabrutinib also
demonstrated a favorable safety profile similar to that observed
with acalabrutinib in BTK inhibitor–naive patients17,31; common
AEs were low grade (grade #2), and no patients required dose
modifications because of AEs. Of the AEs that led to ibrutinib
intolerance, 72% did not recur and 13% recurred at a lower
grade with acalabrutinib treatment. Moreover, 70% of patients
remained on acalabrutinib treatment at a median follow-up of
19 months. Generally, the safety profile of acalabrutinib in
this ibrutinib-intolerant population was consistent with previous
reports of acalabrutinib in BTK inhibitor–naive patients with
relapsed or refractory CLL,17,31 demonstrating that acalabrutinib
tolerability is not decreased in the subset of patients who are
intolerant to ibrutinib. Some AEs associated with ibrutinib
treatment (including atrial fibrillation and bleeding) were also
observed during acalabrutinib treatment; however, the degree
to which these events were associated with BTK signaling
is unclear. An ongoing, head-to-head study in patients with
high-risk CLL (registered at www.clinicaltrials.gov as #NCT02477696)
is under way to delineate the safety profiles of these 2 BTK
inhibitors.
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Figure 4. Acalabrutinib pharmacodynamics in ibrutinib-intolerant patients. (A) BTK occupancy for ibrutinib-intolerant patients with day-1 (D1) predose (Pre)
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method. (B) BCR-induced BTK phosphorylation (p) shown as fold over D1 predose plus exogenous acalabrutinib control. Filtered on D1 predose fold change .1.5 (n 5 15
patients excluded for this reason; n 5 2 patients had insufficient cells to perform the assay). Significance was determined using a paired, 2-tailed, parametric Student t test
comparing time points with D1 predose. ***P , .001, ****P , .0001. C, cycle; Post, postdose; SD, standard deviation.
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Sustained disease control likely requires prolonged, continuous
BTK inhibition. Patients who cannot continue ibrutinib treatment
because of intolerance and who have not progressed while on
therapy may benefit from treatment with acalabrutinib, an
alternative and more selective BTK inhibitor; in such ibrutinib-
intolerant patients, acalabrutinib may provide continued disease
control with improved tolerability. In this relapsed population, all
tested patients were negative for known BTK/PLCg2 resistance
mutations, including C481S, at a sensitivity of 5%. This finding is
consistent with the absence of clinical progression while on prior
ibrutinib treatment and the high response rate with acalabrutinib
treatment. In the current study, patients achieved an ORR
of 76% (Table 3), with response measured relative to clinical
parameters at the start of acalabrutinib treatment. Disease
progression or an indication for treatment was not required for
study entry, and it is possible that the 76% response rate
observed may be higher than expected for patients with more
advanced disease. Also, patients who most recently received
prior ibrutinib treatment may have still been responding to
ibrutinib. However, differing lengths of prior ibrutinib treatment
and time between BTK inhibitor therapies complicate the
interpretation of these responses.
Patients in this study cohort showed near-complete BTK
occupancy with acalabrutinib treatment over the treatment
interval (Figure 4), comparable with results from a previously
studied population of BTK inhibitor–naive patients with relapsed
or refractory CLL who received acalabrutinib.17 High BTK occupancy
was accompanied by inhibition of BCR-mediated BTK phosphor-
ylation, demonstrating the expected pharmacological activity for
acalabrutinib. The drop of BTK phosphorylation below baseline
levels may in part result from a decrease in total BTK protein, as
previously reported.37
Limitations of this study include the retrospective collection of
ibrutinib-related AEs, which were based on patient or physician
recall and judgment. Standardized objective criteria to de-
fine ibrutinib intolerance would have allowed a clearer inter-
pretation of the safety and efficacy of acalabrutinib in this
population. However, of 61 ibrutinib-related AEs that led to
intolerance, 85% did not recur or recurred at a lower grade
with acalabrutinib treatment, including all grade $3 events
that led to ibrutinib discontinuation. It is possible that some
patients in this retrospective study would have tolerated
ibrutinib if rechallenged at a lower dose; the availability of a
more selective BTK inhibitor may have prompted switching
to acalabrutinib instead of optimizing ibrutinib therapy.
Also, because follow-up of acalabrutinib-treated patients was
limited, it is possible that patients may develop intolerance
with continued acalabrutinib treatment. Additionally, central
laboratory assessment of BTK and PLCg2 mutation had a
sensitivity of 5%, which likely did not identify patients with low
levels of resistance to ibrutinib.
Overall, these data show that acalabrutinib is tolerated in most
patients with CLL who develop ibrutinib intolerance, with demon-
strated clinical benefit. The efficacy and safety of acalabrutinib in
patients with relapsed or refractory CLL who are intolerant to
ibrutinib therapy are being further evaluated in an ongoing phase 2
study in which intolerance is more objectively defined (registered
at www.clinicaltrials.gov as #NCT02717611).
Acknowledgments
The authors thank all patients, families, and caregivers who partic-
ipated in the study and Soun Khountham for management of the
patients and contributions to data collection.
This work was supported by grants R35 CA197734 and R01
CA177292 from the National Cancer Institute, National Institutes of
Health (J.C.B.) and by Acerta Pharma, which also funded medical
writing support provided by Team 9 Science.
Authorship
Contribution: F.T.A. drafted the initial and final versions of this
paper; all authors contributed to the design of the study and/or
interpretation of data for this article, contributed to drafts of
the article, and approved the final version to be published;
and all authors had access to the data contained within this
manuscript.
Conflict-of-interest disclosure: F.T.A. has been a consultant for
AbbVie, Janssen, Gilead, Sunesis, AstraZeneca, Genentech, and
Pharmacyclics, received research funding from Innate Pharma and
Pharmacyclics, and served on speakers’ bureaus for AstraZeneca
and AbbVie. A.S. has been a consultant for and has received
honoraria from AbbVie, Gilead, GlaxoSmithKline, Janssen,
Novartis, and Roche. J.R.B. has been a consultant for AbbVie,
Astellas Pharma, AstraZeneca, Celgene, Gilead, Verastem Phar-
maceuticals, Janssen, Pfizer, Pharmacyclics, Redx, Roche/
Genentech, and Sun BioPharma. R.R.F. has been a consultant for
AbbVie, Acerta Pharma, Genentech, Gilead, Incyte, Janssen, Loxo
Oncology, Pharmacyclics, Sunesis, TG Therapeutics, and Vera-
stem. J.M.P. has been a consultant for Gilead and Pharmacyclics
and has equity ownership in and received research funding from
Actinium Pharmaceuticals. P.H. has been a consultant for AbbVie,
Acerta Pharma, Alexion Pharmaceuticals, Gilead, and Janssen, has
received honoraria from AbbVie, Acerta Pharma, Alexion Pharma-
ceuticals, Gilead, and Janssen, and has received research funding
from AbbVie, Gilead, Janssen, GlaxoSmithKline, Pharmacyclics, and
Roche. D.M.S. has received research funding from the Lymphoma
Research Foundation. J.W. has been a consultant for Janssen and
received research funding from Acerta, AbbVie, Karyopharm, and
Morphosys. P.C. is an employee of Acerta Pharma. M.M.F. is an
employee of and holds stock in AstraZeneca. B.L. is an employee
of AstraZeneca. A.H. and R.I. are patent holders and employees of
Acerta Pharma and have equity ownership. E.B., M.H.W., and P.P.
are employees of Acerta Pharma and have equity ownership.
J.C.B. has received research funding from Acerta Pharma, Gen-
entech, Janssen, and Pharmacyclics.
The current affiliation for P.C. is Amgen, South San Francisco, CA.
ORCID profiles: F.T.A., 0000-0003-1813-9812; P.H., 0000-
0001-5617-4403; D.M.S., 0000-0001-9188-5008.
Correspondence: Farrukh T. Awan, Division of Hematology/
Oncology, Harold C. Simmons Comprehensive Cancer Center,
University of Texas Southwestern Medical Center, 5323 Harry
Hines Blvd, Dallas, TX 75390-8565; e-mail: farrukh.awan@
utsouthwestern.edu; and John C. Byrd, The Ohio State Uni-
versity Comprehensive Cancer Center, Arthur G. James Cancer
Hospital and Richard J. Solove Research Institute, 320 W. 10th
Ave, Columbus, OH 43210; e-mail: john.byrd@osumc.edu.
1560 AWAN et al 14 MAY 2019 x VOLUME 3, NUMBER 9
References
1. Union for International Cancer Control. Chronic lymphocytic leukemia: 2014 review of cancer medicines on the WHO List of Essential Medicines.
https://www.who.int/selection_medicines/committees/expert/20/applications/CLL.pdf. Accessed 1 May 2019.
2. Burger JA, Wiestner A. Targeting B cell receptor signalling in cancer: preclinical and clinical advances. Nat Rev Cancer. 2018;18(3):148-167.
3. Byrd JC, Jones JJ, Woyach JA, Johnson AJ, Flynn JM. Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing
clinician. J Clin Oncol. 2014;32(27):3039-3047.
4. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32-42.
5. Byrd JC, Brown JR, O’Brien S, et al; RESONATE Investigators. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J
Med. 2014;371(3):213-223.
6. Burger JA, Tedeschi A, Barr PM, et al; RESONATE-2 Investigators. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J
Med. 2015;373(25):2425-2437.
7. Byrd JC, Furman RR, Coutre SE, et al. Three-year follow-up of treatment-naı¨ve and previously treated patients with CLL and SLL receiving single-agent
ibrutinib. Blood. 2015;125(16):2497-2506.
8. Chanan-Khan A, Cramer P, Demirkan F, et al; HELIOS investigators. Ibrutinib combined with bendamustine and rituximab compared with placebo,
bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind,
phase 3 study. Lancet Oncol. 2016;17(2):200-211.
9. Jain P, Keating M, Wierda W, et al. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood. 2015;125(13):
2062-2067.
10. Jain P, Thompson PA, Keating M, et al. Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib. Cancer. 2017;
123(12):2268-2273.
11. de Claro RA, McGinn KM, Verdun N, et al. FDA approval: ibrutinib for patients with previously treated mantle cell lymphoma and previously treated chronic
lymphocytic leukemia. Clin Cancer Res. 2015;21(16):3586-3590.
12. Sharman JP, Black-Shinn JL, Clark J, Bitman B. Understanding ibrutinib treatment discontinuation patterns for chronic lymphocytic leukemia [abstract].
Blood. 2017;130(suppl 1). Abstract 4060.
13. Mato AR, Hill BT, Lamanna N, et al. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter
study of 683 patients. Ann Oncol. 2017;28(5):1050-1056.
14. Mato AR, Nabhan C, Thompson MC, et al. Toxicities and outcomes of 621 ibrutinib-treated patients in the United States: a real-world analysis.
Haematologica. 2018;103(5):874-879.
15. Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of
autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA. 2010;107(29):13075-13080.
16. Barf T, Covey T, Izumi R, et al. Acalabrutinib (ACP-196): a covalent Bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency
profile. J Pharmacol Exp Ther. 2017;363(2):240-252.
17. Byrd JC, Harrington B, O’Brien S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):323-332.
18. Department of Health and Human Services, Public Health Service, US Food and Drug Administration, Center for Drug Evaluation and Research.
Pharmacology/toxicology NDA review and evaluation (NDA 205552; Imbruvica [ibrutinib]). https://www.accessdata.fda.gov/drugsatfda_docs/nda/
2013/205552Orig1s000PharmR.pdf. Accessed 1 May 2019.
19. Smith-Garvin JE, Koretzky GA, Jordan MS. T cell activation. Annu Rev Immunol. 2009;27(1):591-619.
20. Lowell CA. Src-family and Syk kinases in activating and inhibitory pathways in innate immune cells: signaling cross talk. Cold Spring Harb Perspect Biol.
2011;3(3):a002352.
21. Atherly LO, Brehm MA, Welsh RM, Berg LJ. Tec kinases Itk and Rlk are required for CD81 T cell responses to virus infection independent of their role in
CD41 T cell help. J Immunol. 2006;176(3):1571-1581.
22. Byrne JC, Nı´ Gabhann J, Stacey KB, et al. Bruton’s tyrosine kinase is required for apoptotic cell uptake via regulating the phosphorylation and localization
of calreticulin. J Immunol. 2013;190(10):5207-5215.
23. Da Roit F, Engelberts PJ, Taylor RP, et al. Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for
combination therapy. Haematologica. 2015;100(1):77-86.
24. Feng M, Chen JY, Weissman-Tsukamoto R, et al. Macrophages eat cancer cells using their own calreticulin as a guide: roles of TLR and Btk. Proc Natl
Acad Sci USA. 2015;112(7):2145-2150.
25. Golay J, Ubiali G, Introna M. The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable in vitro activity against chronic
lymphocytic leukemia B-cells with CD20 antibodies. Haematologica. 2017;102(10):e400-e403.
26. Kohrt HE, Sagiv-Barfi I, Rafiq S, et al. Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. Blood. 2014;123(12):1957-1960.
27. Oda A, Ikeda Y, Ochs HD, et al. Rapid tyrosine phosphorylation and activation of Bruton’s tyrosine/Tec kinases in platelets induced by collagen binding or
CD32 cross-linking. Blood. 2000;95(5):1663-1670.
28. Senis YA, Mazharian A, Mori J. Src family kinases: at the forefront of platelet activation. Blood. 2014;124(13):2013-2024.
14 MAY 2019 x VOLUME 3, NUMBER 9 ACALABRUTINIB MONOTHERAPY IN IBRUTINIB INTOLERANCE 1561
29. Wang M, Rule S, Zinzani PL, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.
Lancet. 2018;391(10121):659-667.
30. Patel V, Balakrishnan K, Bibikova E, et al. Comparison of acalabrutinib, a selective Bruton tyrosine kinase inhibitor, with ibrutinib in chronic lymphocytic
leukemia cells. Clin Cancer Res. 2017;23(14):3734-3743.
31. Byrd JC, WierdaWG, Schuh A, et al. Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated results from
the phase 1/2 ACE-CL-001 study [abstract]. Blood. 2017;130(suppl 1). Abstract 498.
32. Hallek M, Cheson BD, Catovsky D, et al; International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of
chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-
Working Group 1996 guidelines. Blood. 2008;111(12):5446-5456.
33. Cheson BD, Ansell S, Schwartz L, et al. Refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy.
Blood. 2016;128(21):2489-2496.
34. Lai Z, Markovets A, Ahdesmaki M, et al. VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research.Nucleic Acids Res.
2016;44(11):e108.
35. AstraZeneca. Clinical trials disclosure commitment. https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Accessed 1 May 2019.
36. Do¨hner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910-1916.
37. Covey T, Gulrajani M, Cheung J, et al. Pharmacodynamic evaluation of acalabrutinib in relapsed/refractory and treatment-naive patients with chronic
lymphocytic leukemia (CLL) in the phase 1/2 ACE-CL-001 study [abstract]. Blood. 2017;130(suppl 1). Abstract 1741.
1562 AWAN et al 14 MAY 2019 x VOLUME 3, NUMBER 9
